GLOW dosage & cycles.

Daily GLOW peptide dosage

3.5 mg of a 5:1:1 GLOW blend contains 2.5 mg GHK-Cu, 500 mcg BPC-157 and 500 mcg TB-500. An original use account documents that daily total on five days each week, followed by two days off. The same account describes pronounced afternoon tiredness. [1]

Attributed use amounts, not a tested starting dose or a recommendation. The author's concurrent treatment included testosterone replacement.

Twice-weekly schedules also exist. One clinic portal lists 1.5, 3.0 and 4.7 mg total blend per administration, twice weekly, for eight to twelve weeks. Its 3 mg example adds up to 6 mg per week—far less than 3.5 mg on five days. These are different schedules, not interchangeable instructions. [2]

Total blend and individual ingredients

The supplied 70 mg vial contains 50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500. GHK-Cu accounts for five sevenths of every portion; each other ingredient accounts for one seventh. The documented TB-500 ingredient is full-length, 43-amino-acid thymosin beta-4. [3]

Composition examples, not a dose ladder. Adding water changes concentration, not the 5:1:1 ratio.

“2 mg GHK-Cu” means 2.8 mg of this complete blend. Entering 2 mg as the total would give about 1.43 mg GHK-Cu and 286 mcg of each other peptide. A fixed blend cannot raise BPC-157 while keeping GHK-Cu unchanged.

Reconstituting a 70 mg GLOW vial

70 mg in 2 mL of final solution gives 35 mg/mL total blend: 25 mg/mL GHK-Cu, 5 mg/mL BPC-157 and 5 mg/mL TB-500. At that concentration, 0.1 mL contains 3.5 mg total.

Laboratory concentration example. The supplied product documents do not specify a validated diluent or mixing volume. The original use account used 2 mL of bacteriostatic water; that does not establish a preparation instruction for this product. [1] [3]

The sealed powder has different storage instructions: −20°C (−4°F), dry and protected from light. Its powder-lot expiry does not become the expiry of a mixed vial. A clear blue solution is its expected appearance, not a sterility test. [3]

General subcutaneous injection sites

Subcutaneous means the fatty layer beneath the skin. General medication sites include the abdomen, outer upper thighs, and side or back of the upper arms. Choose healthy skin, change spots, and keep abdominal injections at least 2 inches (about 5 cm) from the belly button. [6]

The face, joints, tendons and ligaments are not targets in this general diagram. Skin-related interest in GLOW does not supply a reason to inject it into the face. For a prescribed injectable medicine, the clinician should confirm the route and demonstrate technique.

Morning or evening, food and time off

Splitting an amount preserves the daily total only if each portion is smaller. A separate three-month account used 1.75 mg in the morning and 1.75 mg before bed: 3.5 mg daily, including 2.5 mg GHK-Cu and 500 mcg of each other ingredient. Taking 3.5 mg twice daily would double that exposure. [8]

Marked tiredness or dizziness needs assessment; moving the same amount to bedtime does not identify its cause. See the documented symptom timelines.

GLOW dosage calculator: mg, mL and U-100 units

Enter your target total-blend amount first. Set the vial strength and final mixed volume to match your preparation.

One U-100 unit represents 0.01 mL. It does not identify a peptide amount until the concentration is known. A 10-unit volume from a 70 mg vial in 3 mL contains about 2.33 mg total; the same volume from a 2 mL solution contains 3.5 mg.

Final-volume scenarios, not alternative mixing prescriptions. Rounded concentrations are displayed; the calculations use the full values. A pen click is not a U-100 unit.

Daily and weekly totals

Weekly totals calculated from the stated amounts and frequencies. The last row assumes seven dosing days. Figures describe exposure, not comparative effectiveness. [2] [1] [8]

Body weight and dose escalation

The examples use fixed milligrams, not a tested mg-per-kilogram formula. A heavier adult does not automatically need proportionally more. Increasing this blend raises all three ingredients together; a calculation based only on BPC-157 can overlook a fivefold larger GHK-Cu amount.

GLOW and Wolverine Stack amounts

1 mg Wolverine Stack and 1 mg GLOW have different contents. The supplied 1:1 Wolverine Stack vial provides 500 mcg BPC-157 + 500 mcg TB-500 per 1 mg. Matching those two ingredient amounts with GLOW requires 3.5 mg total and also adds 2.5 mg GHK-Cu. This is composition arithmetic, not a substitute dosing instruction. Wolverine Peptide dosage and ratios →

GLOW cycle length

Eight to twelve weeks appears in the clinic portal; one to three months appears in the separate clinic handout. The latter also specifies five dosing days each week and one month off afterward. Their duration ranges do not make the schedules equivalent: two administrations a week and five a week produce different cumulative amounts. [2] [7]

The three-month personal account combined injected GLOW with topical GHK-Cu/Snap-8, testosterone and other peptides. It documents a duration, but cannot establish that three months is the best length or that GLOW alone caused the cosmetic result. [8]

There is no measured whole-blend half-life that turns these schedules into a single required frequency. The GHK-Cu, BPC-157 and thymosin beta-4 ingredients are different molecules. Do not convert an ingredient's animal half-life or intravenous study into a daily GLOW injection schedule.

Longer exposure also means more time for unwanted symptoms to appear. A week without symptoms is not proof that a twelve-week course will remain symptom-free. GLOW results and observed timelines →

GLOW pen concentration and amount

The supplied pen holds 3 mL at a nominal 50 mg/mL: 150 mg total blend. It is already in solution. Its listed ingredients are 107 mg GHK-Cu + 21.4 mg BPC-157 + 21.4 mg TB-500; their 149.8 mg sum reflects rounded specifications. [3]

0.07 mL is a volume calculation, not a click setting. A verified volume per click or manufacturer dosing scale has not been supplied. The pen's 3 mL capacity cannot provide that calibration, and the vial calculator should not be used to invent a dial setting.

Keep the pen at 2–8°C (36–46°F), protected from light; do not freeze it. No in-use lifespan has been supplied. Pen specifications and COA scope → [3]

Total milligrams, vials and pens per course

At 3.5 mg per administration, a 70 mg vial contains 20 mathematical portions. At five administrations a week, that represents four weeks of label-based quantity. At daily use, it represents 20 days.

The 140 mg example contains 100 mg GHK-Cu, 20 mg BPC-157 and 20 mg TB-500. Containers are rounded up; the figures exclude transfer losses, pen priming, residual liquid and discard requirements.

A quantity that spans eight weeks is not proof that an opened vial or pen remains usable for eight weeks. Product-specific in-use limits and verified device settings are still required. Compare the 70 mg vial and 150 mg pen before treating nominal capacity as deliverable quantity.